Original article: Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma
- 1 September 1992
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 3 (8) , 651-656
- https://doi.org/10.1093/oxfordjournals.annonc.a058296
Abstract
We have studied the pharmacokinetics of epirubicin after its administration in sarcoma patients either as an i.v. bolus or as a 48-h infusion (5 courses each; 9 patients in total). Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion. Pharmacokinetic parameters such as total plasma clearance, total volume of distribution, mean residence time and elimination half-life were similar, irrespective of the duration of the administration. In contrast, the relative amounts of the metabolites of epirubicin were reduced when the drug was administered over 48 h; in particular, the plasma levels of epirubicin glucuronide never exceeded those of epirubicin, which always occur after bolus injection. This may result from a lower availability of epirubicin for metabolism. These results now require validation in a larger group of patients using a cross-over design.Keywords
This publication has 25 references indexed in Scilit:
- A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factorsCancer, 1991
- Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1991
- Epirubicin and DTIC (EDIC) for Advanced Soft-Tissue SarcomasOncology, 1991
- Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1989
- Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma groupEuropean Journal of Cancer and Clinical Oncology, 1987
- Steady-state dosage regimen calculations in linear pharmacokineticsInternational Journal of Bio-Medical Computing, 1986
- Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patientsEuropean Journal of Cancer and Clinical Oncology, 1985
- Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4′-epidoxorubicinEuropean Journal of Cancer and Clinical Oncology, 1984
- 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical dataCancer Treatment Reviews, 1983
- Liquid Chromatographic Analysis of Adriamycin and Metabolites in Biological FluidsJournal of Liquid Chromatography, 1978